NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July ...
NeoGenomics (NEO) shares ended the last trading session 7.2% higher at $11.13. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...
StockStory.org on MSN
A look back at testing & diagnostics services stocks’ Q1 earnings: NeoGenomics (NASDAQ:NEO) vs the rest of the pack
Looking back on testing & diagnostics services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, ...
(NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today that it has commenced a private offering of $275 million aggregate principal amount ...
NeoGenomics ( (NEO) ) has shared an announcement. NeoGenomics, on June 22, 2026, detailed a financing transaction in which it sold new convertible senior notes to initial purchasers under Securities ...
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first ...
On Friday, the District Court for the Middle District of North Carolina issued a ruling invalidating specific claims in two patents that Natera Inc. (NASDAQ:NTRA) asserted against NeoGenomics, Inc.'s ...
NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. I ...
(NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today the pricing of its previously announced private offering of $275 million aggregate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results